Should sulfonylureas remain an acceptable first-Line add-On to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 166-169

  Abrahamson, Martin J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BROMOCRIPTINE MESILATE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADD ON THERAPY; ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONSENSUS; DIARRHEA; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDEMA; FLATULENCE; FRACTURE; GLYCEMIC CONTROL; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; POLYURIA; PRACTICE GUIDELINE; PRESCRIPTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 84920053433     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1945     Document Type: Article

References (25)

1. American Diabetes Association. Standards of medical care in diabetesd2015. Diabetes Care 2015;38(Suppl. 1):S5-S87
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statementdexecutive summary. Endocr Pract 2013;19(Suppl.):536-557
3. Leese GP, Wang J, Broomhall J, et al.; DARTS/ MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 2003;26:1176-1180
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. Kahn SE, Haffner SM, HeiseMA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
6. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-394
7. Ha WC, Oh SJ, Kim JH, et al. Severe hypoglycemia is a serious complication and becoming an economic burden in diabetes. Diabetes Metab J 2012;36:280-284
8. Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012;26: 399-406
9. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Clinical implications of UGDP results. JAMA 1971;218:1400-1410
10. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136
11. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-537
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
13. Frye RL, August P, Brooks MM, et al.; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515
14. Jollis JG, Simpson RJ Jr, CascioWE, Chowdhury MK, Crouse JR 3rd, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999;138: S376-S380
15. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157:601-610
16. Hirst JA, Farmer AJ, Dyar A, Lung TWC, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013;56:973-984
17. Al-Ozairi E, Sibal L, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas? Diabetes Care 2007; 30:1677-1680
18. Nauck M, Frid A, Hermansen K, et al. Longterm efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15:204-212
19. Gallwitz B, Rosenstock J, Rauch T, et al. 2- year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-483
20. Nathan DM, Buse JB, Kahn SE, et al.; GRADE Study Research Group. Rationale and design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261
21. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
22. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 2011;183:E1213-E1220
23. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-1576
24. Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation 2014;129: 2567-2573
25. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: Safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2014;37:2647-2659